<SEC-DOCUMENT>0001325447-17-000014.txt : 20170206
<SEC-HEADER>0001325447-17-000014.hdr.sgml : 20170206
<ACCEPTANCE-DATETIME>20170206143058
ACCESSION NUMBER:		0001325447-17-000014
CONFORMED SUBMISSION TYPE:	SC 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20170206
DATE AS OF CHANGE:		20170206

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			THRESHOLD PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001183765
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943409596
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-81377
		FILM NUMBER:		17575148

	BUSINESS ADDRESS:	
		STREET 1:		170 HARBOR WAY
		STREET 2:		SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650 474 8200

	MAIL ADDRESS:	
		STREET 1:		170 HARBOR WAY
		STREET 2:		SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			First Eagle Investment Management, LLC
		CENTRAL INDEX KEY:			0001325447
		IRS NUMBER:				571156902
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13G

	BUSINESS ADDRESS:	
		STREET 1:		1345 AVENUE OF THE AMERICAS
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105
		BUSINESS PHONE:		212-698-3128

	MAIL ADDRESS:	
		STREET 1:		1345 AVENUE OF THE AMERICAS
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arnhold & S. Bleichroeder Advisers, LLC
		DATE OF NAME CHANGE:	20050429
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13G
<SEQUENCE>1
<FILENAME>threshold12311613g.txt
<TEXT>
<PAGE>


UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.  20549


Schedule 13G


Under the Securities Exchange Act of 1934
(Amendment No. )
(RULE 13d-102)


Information to be included in statements filed
pursuant to Rule 13d-1 (b) (c) and (d) and Amendments thereto
filed pursuant to Rule 13d-2 (b).


Threshold Pharmaceuticals Inc
(Name of Issuer)


Common shares
(Title of Class of Securities)

885807206
(CUSIP/SEDOL Number)


December 31, 2016
(Date of Event which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant
to which this Schedule is filed:

[X] 	Rule 13d-1 (b)
[ ]	Rule 13d-1 (c)
[ ]	Rule 13d-1 (d)

	*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided
in a prior cover page.

	The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).


<PAGE>

SCHEDULE 13G


Issuer: Threshold Pharmaceuticals Inc  CUSIP No.: 885807206

1	NAMES OF REPORTING PERSONS I.R.S.
	IDENTIFICATION NOS. OF ABOVE PERSONS

	First Eagle Investment Management, LLC
	Tax ID # 57-1156902


2	CHECK THE APPROPRIATE BOX IF A MEMBER
	OF A GROUP
	(a)
	(b)


3	SEC USE ONLY


4	CITIZENSHIP OR PLACE OF ORGANIZATION

	State of Delaware


NUMBER OF SHARES	5  SOLE VOTING POWER - 7,093,802
BENEFICIALLY  		6  SHARED VOTING POWER - 0
OWNED BY EACH	 	7  SOLE DISPOSITIVE POWER - 7,093,802
REPORTING PERSON       	8  SHARED DISPOSITIVE POWER - 0
WITH:


9	AGGREGATE AMOUNT BENEFICIALLY OWNED
	BY EACH REPORTING PERSON

	7,093,802


10	CHECK IF THE AGGREGATE AMOUNT IN
	ROW (11) EXCLUDES CERTAIN SHARES

	N/A


11	PERCENT OF CLASS REPRESENTED BY AMOUNT
   	IN ROW 9:

 	9.91%


12	TYPE OF REPORTING PERSON

	IA


<PAGE>

SCHEDULE 13G

Issuer: Threshold Pharmaceuticals Inc   CUSIP No.: 885807206


ITEM 1

(a)	Name of Issuer: Threshold Pharmaceuticals Inc


(b)	Address of Issuer's Principal Executive Offices:

	170 Harbor Way, Suite 300
	South San Francisco, CA 94080


ITEM 2

(a)	Name of Person Filing: First Eagle Investment Management, LLC

(b)	Address of Principal Business Office:

	1345 Avenue of the Americas
	New York, NY 10105


(c)	Citizenship: Delaware, USA


(d)	Title of Class of Securities:

	Common Stock


(e)	CUSIP No.: 885807206


ITEM 3

If this statement is filed pursuant to Sections 240.
13d-1(b), or 240.13d-2(b) or (c), check whether
the person filing is a:

(a)	[  ]	Broker or dealer registered under
		Section 15 of the Act (15 U.S.C. 78o);

(b)	[  ]	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) 	[  ]	Insurance Company as defined in section
		3(a)(19) of the Act (15 U.S.C. 78C);

(d)	[  ]	Investment company registered under Section
		8 of the Investment Company Act if 1940
		(15 U.S.C. 80a-8);

(e)	[X]	An investment adviser in accordance with Section
		240.13d-1(b)(1)(ii)(E);

(f)	[  ]	An employee benefit plan or endowment fund in accordance with
		Section 240.13d-1(b)(1)(ii)(F);

(g)	[  ]	A parent holding company or control person in accordance with
		Section 240.13d-1(b)(1)(ii)(G);

(h)	[  ]	A savings associations as defined in Section 3(b) of the
		Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	[  ]	A church plan that is excluded from the
		definition of an insurance company under Section 3 (c)(14) of
		the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	[  ]	Group, in accordance with section 240.13d-1 (b)(1)(ii)(J).


<PAGE>

SCHEDULE 13G

Issuer: Threshold Pharmaceuticals Inc  CUSIP No.: 885807206

ITEM 4.	Ownership.

	N/A


ITEM 5. Ownership of Five Percent or Less of a Class.

	N/A


ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

	First Eagle Investment Management, LLC (FEIM), an investment adviser
	registered under Section 203 of the Investment Advisers Act of 1940,
	is deemed to be the beneficial owner of 7,093,802 shares, or 9.91%
	of the common stock believed to be outstanding as a result of
	acting as investment adviser to various clients. Clients of FEIM
	have the right to receive and the ultimate power to direct the
	receipt of dividends from, or the proceeds of the sale of, such
	securities.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
	SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL
	PERSON.

	N/A


ITEM 8. Identification and Classification of Members of the Group.

	N/A


ITEM 9. Notice of Dissolution of Group

	N/A


ITEM 10. Certification

	By signing below I certify that, to the best of my knowledge and
	belief, the securities referred to above were acquired and held in the
	ordinary course of business and were not acquired and are not held for the
	purpose of or with the effect of changing or influencing the control of the
	issuer of such securities and were not acquired and are not held in
	connection with or as a participant in any transaction having that purpose
	of effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.

Date:		February 6, 2017

Signature:	/s/ Michael M. Kellen

Name/Title:	Michael M. Kellen, /Director

</PAGE>


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>